Although originally approved for diabetes, researchers discovered something important: GLP-1 medications consistently reduce inflammation in fat tissue, the gut, the blood vessels, and even the immune system. This has enormous implications for arthritis and autoimmune diseases.
In January 2025, you said that the new diabetes and weight-loss medications called GLP-1 drugs appeared to reduce the risk of many major diseases, by reducing inflammation.
In the present study, researchers summarized the anti-inflammatory effects of GLP-1 medicines, covering emerging concepts and their clinical relevance.
Recent evidence has highlighted the therapeutic capacity of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), already employed in treating T2DM and obesity, in modulating systemic and intestinal inflammatory responses.
growing body of research suggests that GLP-1 drugs do more than control appetite and blood sugar. They could also fight inflammation
.png "GLP-1 Therapy for Inflammation Control: A New Frontier in Health ...")
